Alzheimer’s disease affects over 20 million people in Europe alone, and that figure is expected to double over the next 3 decades. The majority of people with Alzheimer’s disease have other health problems, such as cardiovascular, psychiatric and musculoskeletal diseases. This makes it even harder to diagnose and manage Alzheimer’s disease.
The aim of PROMINENT is to set up a digital platform that will improve the diagnosis and personalised treatment of people with Alzheimer’s disease coupled with other diseases. It will draw on existing artificial intelligence tools to create an open, interoperable platform capable of interacting with multiple systems to integrate diverse data from sources such as medical records, mobile devices and imaging repositories.
Advanced analytical tools embedded in the platform will highlight the most likely outcomes for individual patients, along with personalised, evidence-based suggestions for the most appropriate ways of managing the patient’s health. For clinicians, the platform will help them select the right tests and treatments for each patient. Meanwhile the platform will provide patients and care partners with personalised, relevant, easy-to-understand information on their brain health. At the same time, the platform will make it easier to assess how well treatments work in the real world. This will be particularly important as and when disease-modifying treatments for Alzheimer’s disease start to be approved and used in regular clinical practice.
“In PROMINENT we are building a platform for introducing new disease-modifying therapies for Alzheimer’s disease, and for collecting data needed to understand how these treatments benefit patients and their caregivers,” said PROMINENT Principal Investigator Dr Linus Jönsson, Professor of Health Economics at Karolinska Institutet. ”PROMINENT will support clinicians in getting the most out of new technologies to diagnose and treat Alzheimer’s disease for their patients.”
While the platform will focus on Alzheimer’s disease, the project hopes that it could ultimately have an impact on the care of patients with other neurodegenerative diseases.